SEARCH:   Advanced

Blood, 15 February 2007, Vol. 109, No. 4, pp. 1782-1789. Prepublished online as a Blood First Edition Paper on October 24, 2006; DOI 10.1182/blood-2006-06-031682. This Article Full Text (PDF) All Versions of this Article: blood-2006-06-031682v1 109/4/1782    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Oehler, V. G. Articles by Radich, J. P. Search for Related Content PubMed PubMed Citation Articles by Oehler, V. G. Articles by Radich, J. P. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted June 27, 2006 Accepted September 7, 2006 The effects of imatinib mesylate treatment before allogeneic transplant for chronic myeloid leukemia Vivian G. Oehler*, Ted Gooley, David S Snyder, Laura Johnston, Allen Lin, Carrie C Cummings, Su Chu, Ravi Bhatia, Stephen J. Forman, Robert S. Negrin, Frederick R. Appelbaum, and Jerald P. Radich Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA Division of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA Division of Bone Marrow Transplantation, Stanford University, Stanford, CA * Corresponding author; email: voehler{at}u.washington.edu. The impact of imatinib mesylate (IM) treatment for chronic myeloid leukemia (CML) on subsequent allogeneic transplant is uncertain. To better understand this relationship, we retrospectively compared 145 CML patients receiving IM for a minimum of 3 months before allogeneic hematopoietic cell transplant (HCT) to 231 CML patients who did not. IM treatment was associated with no increase in early hepatotoxicity or engraftment delay after HCT compared to the historical cohort. In addition, there was no statistically significant difference in the IM-treated cohort compared to the historical cohort with regard to overall survival, disease-free survival, relapse, and non-relapse mortality. For chronic phase (CP) patients, IM response prior to HCT was associated with post-HCT outcome. Patients transplanted in CP with a suboptimal response or a loss of response on IM had a statistically significantly higher hazard of mortality when compared to CP patients who achieved a complete cytogenetic response (CCR) or major cytogenetic response (MCR) on IM (HR=5.31, 95% CI 1.13-25.05, p=0.03). These data indicate that pre-HCT IM is not associated with increased transplant-related morbidity (TRM) or worse outcomes. However, patients with a suboptimal or loss of IM response before HCT do worse, suggesting a more aggressive disease course for these patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. M. Goldman How I treat chronic myeloid leukemia in the imatinib era Blood, October 15, 2007; 110(8): 2828 - 2837. [Abstract] [Full Text] [PDF] J. P. Radich The Biology of CML Blast Crisis Hematology, January 1, 2007; 2007(1): 384 - 391. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020